SLC1A2 Protein — EAAT2/GLT-1
Overview
SLC1A2, encoding the excitatory amino acid transporter 2 (EAAT2), is the primary glutamate clearance protein in the central nervous system. Also known as GLT-1 (glutamate transporter-1) in rodents, EAAT2 is a high-capacity, sodium-dependent glutamate transporter predominantly expressed on astrocytes throughout the brain and spinal cord. This transporter accounts for approximately 90% of glutamate uptake capacity in the adult brain, making it the dominant mechanism for removing glutamate from the synaptic cleft and extracellular space. EAAT2 dysfunction and downregulation are hallmark features of multiple neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS), where SLC1A2 alterations have been extensively documented.
Function/Biology
EAAT2 operates as an electrogenic transporter that couples glutamate uptake to the inward movement of three sodium ions and the concurrent counter-transport of one potassium ion. This active transport mechanism requires ATP hydrolysis and maintains the electrochemical gradients necessary for efficient glutamate clearance. The transporter has two functional conformations—an outward-facing state that accepts glutamate from the synaptic space, and an inward-facing state that releases glutamate into the astrocytic cytoplasm for metabolic processing.
...SLC1A2 Protein — EAAT2/GLT-1
Overview
SLC1A2, encoding the excitatory amino acid transporter 2 (EAAT2), is the primary glutamate clearance protein in the central nervous system. Also known as GLT-1 (glutamate transporter-1) in rodents, EAAT2 is a high-capacity, sodium-dependent glutamate transporter predominantly expressed on astrocytes throughout the brain and spinal cord. This transporter accounts for approximately 90% of glutamate uptake capacity in the adult brain, making it the dominant mechanism for removing glutamate from the synaptic cleft and extracellular space. EAAT2 dysfunction and downregulation are hallmark features of multiple neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS), where SLC1A2 alterations have been extensively documented.
Function/Biology
EAAT2 operates as an electrogenic transporter that couples glutamate uptake to the inward movement of three sodium ions and the concurrent counter-transport of one potassium ion. This active transport mechanism requires ATP hydrolysis and maintains the electrochemical gradients necessary for efficient glutamate clearance. The transporter has two functional conformations—an outward-facing state that accepts glutamate from the synaptic space, and an inward-facing state that releases glutamate into the astrocytic cytoplasm for metabolic processing.
The protein contains twelve transmembrane domains with a large extracellular loop forming the glutamate binding pocket. Upon binding glutamate, a conformational change occurs that triggers sodium and potassium ion movements. The transported glutamate is subsequently metabolized by astrocytes through the glutamate-glutamine cycle, where glutaminase converts glutamate to glutamine, which is then released and recaptured by neurons for neurotransmitter resynthesis.
EAAT2 expression is tightly regulated by multiple factors including neuronal activity, growth factors, and inflammatory cytokines. The SLC1A2 gene contains responsive elements that respond to nuclear factor-kappa B (NF-κB) and other transcription factors, allowing dynamic adjustment of transporter levels in response to neuronal demands and pathological conditions.
Role in Neurodegeneration
Glutamate excitotoxicity—excessive neuronal stimulation by glutamate—is a central mechanism in multiple neurodegenerative conditions. Reduced EAAT2 function leads to glutamate accumulation in the extracellular space, causing pathological activation of NMDA and AMPA receptors on neurons, ultimately triggering calcium overload, mitochondrial dysfunction, and neuronal death.
In ALS, EAAT2 is markedly reduced in affected motor neurons and surrounding glial cells, even in non-familial cases where no genetic mutations are identified. This downregulation occurs early in disease progression and correlates with motor neuron vulnerability. Some ALS patients carry mutations in the SLC1A2 promoter or splice variants that reduce transporter expression, while others show acquired loss through post-transcriptional mechanisms or glial activation changes.
Alzheimer's disease pathology involves impaired glutamate clearance contributing to both excitotoxicity and disruption of long-term potentiation necessary for memory formation. Parkinson's disease also demonstrates reduced EAAT2 expression in substantia nigra, correlating with dopaminergic neuron loss. Huntington's disease shows EAAT2 dysfunction in striatal regions, exacerbating polyglutamine-induced excitotoxicity.
Molecular Mechanisms
EAAT2 dysfunction in neurodegeneration occurs through multiple mechanisms. Direct transcriptional downregulation results from altered promoter activity and loss of activating transcription factors. Post-translational modifications, including phosphorylation and ubiquitination, affect transporter stability and localization. Inflammatory cytokines like TNF-α and IL-1β reduce EAAT2 surface expression through internalization and degradation pathways.
Oxidative stress and protein misfolding promote EAAT2 ubiquitination and proteasomal degradation. In ALS, expression of mutant superoxide dismutase 1 (SOD1) or other disease-associated proteins disrupts EAAT2 trafficking and function. Loss of astrocytic glutamate buffering capacity shifts metabolic burden to neurons and intensifies excitotoxic signaling cascades involving calcium/calmodulin-dependent protein kinase II (CaMKII) and calpain activation.
Clinical/Research Significance
EAAT2 represents a promising therapeutic target for neurodegenerative diseases. β-lactam antibiotics like ceftriaxone upregulate EAAT2 expression through NF-κB pathway activation and have shown neuroprotective effects in ALS models. Riluzole, the primary FDA-approved ALS treatment, partially works through EAAT2 enhancement. AMPA receptor antagonists and GLT1 potentiators are under investigation for restoring glutamate clearance capacity.
Biomarker studies indicate that cerebrospinal fluid glutamate levels and astrocytic EAAT2 expression correlate with disease progression in ALS and potentially other neu